We suggest treating the individuals with biallelic pathogenic variants in COQ2, COQ6, and PDSS2 or presenting phenotype suggestive of CoQ10-related glomerulopathy with oral CoQ10 as early as possible. The gene discussed is COQ2; the disease is glomerular disorder.